Article Title: Nine More MFN Deals; Western Drugmakers Turn to China; Chai Discovery’s Raise; and More
Publication Date: December 20, 2025
As reported by Endpoints Weekly, the previous week witnessed a significant turn in strategies of western drugmakers as they pivot towards China. In a bid to connect more with the prospering market in Asia, several MFN (Most Favoured Nation) deals have been signed. The industry also noted Chai Discovery’s latest funding round.
During the week, nine more MFN deals were inked, demonstrating a discernible eagerness among western drugmakers to form alliances in the Chinese market. The MFN status ensures that the country which has been bestowed this will be the recipient of the best trade benefits given by the offering nation. For the multinational pharmaceutical companies, such deals accentuate market access, enable significant supply chain cost reductions and allow leveraging local competencies.
The news additionally highlighted Chai Discovery’s recent fundraising activity, the specifics of which were not detailed in the report. Given the essential role biotech startups play in driving innovation in the field, investors will be keeping an eye on this development to understand potential market impacts and opportunities.
The shift in strategy by western companies towards China represents a notable development in the global biotech industry. China has been accelerating its efforts to bring in foreign investment and talents to bolster its local biotech industry, and this strategic turn among western drug manufacturers is a crucial validation of these efforts.
For investors, the implications of this change in momentum are multifaceted. They indicate a shift in the global biotech market, making China an attractive investment prospect. Also, these deals promise a way to tap into the climbing demand for innovative drugs in China – potentially leading to stronger growth trajectories for western firms operating there.
Irrespective of the ebb and flow of strategies and deals in the industry, one constant remains – the need for credible and timely market intelligence. Here at Industry Informant, we remain committed to providing you with such insights to help navigate the changing currents of the biotech sector.
